In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $23.28 in the last session, up 1.00% from day before closing price of $23.05. In other words, the price has increased by $1.00 from its previous closing price. On the day, 0.53 million shares were traded. VRDN stock price reached its highest trading level at $24.0 during the session, while it also had its lowest trading level at $23.25.
Ratios:
We take a closer look at VRDN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.82 and its Current Ratio is at 15.82. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on September 11, 2024, Reiterated its Buy rating but revised its target price to $38 from $30 previously.
On June 11, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $29.
On June 06, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $23.Goldman initiated its Buy rating on June 06, 2024, with a $23 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.
Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1803799680 and an Enterprise Value of 1138306304. For the stock, the TTM Price-to-Sale (P/S) ratio is 6129.87 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 3952.453 whereas that against EBITDA is -4.549.
Stock Price History:
Over the past 52 weeks, VRDN has reached a high of $25.39, while it has fallen to a 52-week low of $11.01. The 50-Day Moving Average of the stock is 14.18%, while the 200-Day Moving Average is calculated to be 37.18%.
Shares Statistics:
According to the various share statistics, VRDN traded on average about 1.43M shares per day over the past 3-months and 783320 shares per day over the past 10 days. A total of 76.36M shares are outstanding, with a floating share count of 67.61M. Insiders hold about 11.45% of the company’s shares, while institutions hold 82.78% stake in the company. Shares short for VRDN as of 1728950400 were 9791768 with a Short Ratio of 6.87, compared to 1726185600 on 10461877. Therefore, it implies a Short% of Shares Outstanding of 9791768 and a Short% of Float of 14.64.
Earnings Estimates
The current rating of Viridian Therapeutics Inc (VRDN) reflects the combined expertise of 14.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.7 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$3.28 and -$4.14 for the fiscal current year, implying an average EPS of -$3.87. EPS for the following year is -$4.18, with 14.0 analysts recommending between -$3.26 and -$5.34.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for VRDN’s current fiscal year. The highest revenue estimate was $1M, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $280k. In the same quarter a year ago, actual revenue was $314k
